NCT00439465 is a Phase 2 clinical trial of Ex-vivo expanded effector cells in Myeloma, sponsored by Dartmouth-Hitchcock Medical Center.

Who is sponsoring NCT00439465?

NCT00439465 is sponsored by Dartmouth-Hitchcock Medical Center.

What drugs are being tested in NCT00439465?

Interventions in NCT00439465: Ex-vivo expanded effector cells.

What condition does NCT00439465 study?

NCT00439465 studies Myeloma, Transplant-eligible Patients.

Is NCT00439465 still recruiting?

NCT00439465 is currently completed. Last updated 1 March 2019.

Are results published for NCT00439465?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-03-01 · How we verify

NCT00439465

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma

Completed Phase 2 Results posted Last updated 1 March 2019

What this trial tests

Phase 2 trial testing Ex-vivo expanded effector cells in Myeloma in 23 participants. Completed in 30 November 2012.

Timeline

1 January 2007

Primary endpoint
15 October 2012

30 November 2012

Quick facts

Lead sponsor	Dartmouth-Hitchcock Medical Center
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	23
Start date	1 January 2007
Primary completion	15 October 2012
Estimated completion	30 November 2012
Sites	1 location across United States

Drugs / interventions tested

Ex-vivo expanded effector cells — full drug profile →

Conditions studied

Myeloma — all drugs for Myeloma →
Transplant-eligible Patients — all drugs for Transplant-eligible Patients →

Sponsor

Dartmouth-Hitchcock Medical Center

Who can join

Adults 18 to 75, any sex, with Myeloma or Transplant-eligible Patients. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Participants With Adverse Events in All Subjects
Time frame: From initiation of treatment on protocol until Day 100
To establish the safety (toxicity) of myeloma patients treated with high dose melphalan, autologous peripheral blood stem cell transplantation (APBSCT) \& adoptive transfer of cytotoxic effector cells with Interleukin-2 (IL-2) and Recombinant Human Granulocyte Colony Stimulating Factor (GM-CSF).

Sponsor's own description

The purpose of this study is to determine whether the administration of highly effective "killer" cells (cytotoxic T cells), along with Interleukin-2 (IL-2) and Recombinant Human Granulocyte Colony Stimulating Factor (GM-CSF) immediately following Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) will enhance anti-tumor immune reconstitution and improve outcome of Multiple Myeloma patients. The overall hypothesis of this proposal is that immediately following APBSCT the immune reconstitution is optimal to administer "killer" cells, combined with the administration of IL-2 and GM-CSF.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Regulation of NKG2D Stress Ligands and Its Relevance in Cancer Progression.
Jones AB, Rocco A, Lamb LS, Friedman GK, et al · · 2022 · cited 44× · PMID 35565467 · DOI 10.3390/cancers14092339
Good Cop, Bad Cop: Profiling the Immune Landscape in Multiple Myeloma.
Sharma NS, Choudhary B. · · 2023 · cited 8× · PMID 38002311 · DOI 10.3390/biom13111629

Verify or expand the search:

Other recruiting trials for Myeloma

Currently open trials in the same condition.

NCT06487247 — HEME Home Transfusion Program · NA · recruiting
NCT07106671 — A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma · Phase 2 · recruiting
NCT07052916 — A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties · NA · recruiting
NCT07202078 — Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) · Phase 2, PHASE3 · recruiting
NCT07202091 — Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) · Phase 2, PHASE3 · recruiting

Other Dartmouth-Hitchcock Medical Center trials

Trials by the same sponsor.

NCT07325474 — Plan and Protect: Safety Planning for Teens in Rural Emergency Departments · NA · not yet recruiting
NCT07428629 — Piloting an Insomnia Treatment in Patients With Ulcerative Colitis · NA · not yet recruiting
NCT06777511 — Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients · not yet recruiting
NCT07279116 — ABY-029 Head & Neck Trial · Phase 1 · not yet recruiting
NCT07063693 — ABY-029 Glioma Trial · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00439465 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dartmouth-Hitchcock Medical Center
Last refreshed: 1 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00439465.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing